| |NOVEMBER 20248BSV BOOSTS R&D WITH IN-HOUSE BIOLOGICS, EXPANDS WOMEN'S HEALTH PORTFOLIOOBLIQUE THERAPEUTICS & ELI LILLY PARTNER FOR ANTIBODY DEVELOPMENTBSV, Bharat Serums and Vaccines Ltd, has created innovative biologic products internally, showcasing their impressive research and development skills. They have a diverse collection of branded products in women's health, fertility, critical care, and immunoglobulins.Mankind Pharma announced that it has finalized the deal to purchase BSV for a total of Rs 13,768 crore. The company's announcement signifies a major advancement, positioning them as a top player in the Indian market for women's health and fertility drugs, as well as granting them access to other difficult-to-enter products in the critical care sector with established advanced R&D technology platforms, according to a statement from the drug maker."Today, we warmly welcome BSV's 2,500 plus members to Mankind family adding a new chapter to our exciting journey and setting the stage for accelerated growth," Mankind Pharma Vice-chairman and Managing Director Rajeev Juneja stated.Sanjiv Navangul, MD & CEO of BSV, stated that being part of the Mankind Pharma family enhances BSV, making it larger, more robust, and improved."Together, we will now be able to ensure wider access of our specialised and indigenously developed complex treatments to millions of patients in India and across the globe. We will together unlock new possibilities, explore opportunities and maximize potential that will help achieve our priorities and business goals," he added. POOblique Therapeutics, a top biotech company focused on creating new drugs, has partnered with Eli Lilly and Company (Lilly) to use the AbiProt technology in developing antibodies for a valuable target. This collaboration is designed to speed up research and development for new treatments, with the potential to earn milestones and royalties if it proves successful.Oblique will collaborate with Lilly Catalyze360-ExploR&D, an external innovation arm at Lilly that combines enterprise learning, scientific expertise, and top research and development skills to advance partner science.The companies have an agreement signed in November 2023, which is already in place and now extends their collaboration to another valuable target."We are delighted to expand the collaboration between our companies and together create new science to address the unmet medical need in severe diseases. This collaboration with Lilly is of great importance to us and will further strengthen our position within the antibody discovery space," says Christer Nordstedt, CEO at Oblique Therapeutics.Oblique Therapeutics is a biotech company dedicated to creating innovative therapies for serious diseases, with a particular focus on pain management and other health issues. The company employs cutting-edge technology and creative research approaches to identify and develop novel antibody-based drug prospects. POTOP STORIES
< Page 7 | Page 9 >